Amedeo Smart

Free Medical Literature Service


 

Amedeo

Breast Cancer

  Free Subscription

29.01.2024

1 AJR Am J Roentgenol
1 Ann Oncol
4 Ann Surg Oncol
3 BMC Cancer
2 BMJ
1 Br J Cancer
1 Breast Cancer
1 Breast Cancer (Dove Med Press)
3 Breast Cancer Res
16 Breast Cancer Res Treat
3 Cancer
1 Cancer Epidemiol Biomarkers Prev
1 Cancer Lett
1 Clin Breast Cancer
2 Eur J Cancer
1 Eur J Surg Oncol
2 Eur Radiol
1 Gene
1 Int J Cancer
2 J Clin Oncol
1 J Nucl Med
1 J Surg Oncol
1 Lancet
1 Mod Pathol
1 Nature
3 NPJ Breast Cancer
2 Oncol Rep
1 PLoS Comput Biol
3 PLoS One
2 Proc Natl Acad Sci U S A
2 Radiology
1 Semin Oncol



    AJR Am J Roentgenol

  1. PENG Y, Zhang X, Qiu Y, Li B, et al
    Development and Validation of MRI Radiomics Models to Differentiate HER2-Zero, -Low, and -Positive Breast Cancer.
    AJR Am J Roentgenol. 2024 Jan 24. doi: 10.2214/AJR.23.30603.
    >> Share


    Ann Oncol

  2. HARVEY-JONES E, Raghunandan M, Robbez-Masson L, Magraner-Pardo L, et al
    Longitudinal profiling identifies co-occurring BRCA1/2 reversions, TP53BP1, RIF1 and PAXIP1 mutations in PARP inhibitor resistant advanced breast cancer.
    Ann Oncol. 2024 Jan 18:S0923-7534(24)00010-3. doi: 10.1016/j.annonc.2024.
    >> Share


    Ann Surg Oncol

  3. CORTINA CS, Lloren JI, Rogers C, Johnson MK, et al
    Does Neoadjuvant Chemotherapy in Clinical T1-T2 N0 Triple-Negative Breast Cancer Increase the Extent of Axillary Surgery?
    Ann Surg Oncol. 2024 Jan 25. doi: 10.1245/s10434-024-14914.
    >> Share

  4. HIGGINS T, Kantor O, Harrison B, Giordano J, et al
    ASO Visual Abstract: Defining the Biology of Estrogen Receptor-Low Positive Breast Cancer.
    Ann Surg Oncol. 2024 Jan 24. doi: 10.1245/s10434-024-14921.
    >> Share

  5. LAWS A, Leonard S, Hershey E, Stokes S, et al
    Upgrade Rates and Breast Cancer Development Among Germline Pathogenic Variant Carriers with High-Risk Breast Lesions.
    Ann Surg Oncol. 2024 Jan 23. doi: 10.1245/s10434-024-14947.
    >> Share

  6. KOBZEVA-HERZOG A, O'Shea T, Young S, Kenzik K, et al
    ASO Visual Abstract: Breast Cancer Screening and BI-RADS Scoring Trends Before and During the COVID-19 Pandemic in an Academic Safety-Net Hospital.
    Ann Surg Oncol. 2024 Jan 22. doi: 10.1245/s10434-024-14896.
    >> Share


    BMC Cancer

  7. SHAO H, Sun Y, Na Z, Jing H, et al
    Diagnostic value of applying preoperative breast ultrasound and clinicopathologic features to predict axillary lymph node burden in early invasive breast cancer: a study of 1247 patients.
    BMC Cancer. 2024;24:112.
    >> Share

  8. LEE YH, Huang CY, Hsieh YH, Yang CH, et al
    A novel computer-assisted tool for 3D imaging of programmed death-ligand 1 expression in immunofluorescence-stained and optically cleared breast cancer specimens.
    BMC Cancer. 2024;24:121.
    >> Share

  9. YANG ZJ, Xin F, Chen ZJ, Yu Y, et al
    Real-world data on neoadjuvant chemotherapy with dual-anti HER2 therapy in HER2 positive breast cancer.
    BMC Cancer. 2024;24:134.
    >> Share


    BMJ

  10. MANNU GS, Wang Z, Dodwell D, Broggio J, et al
    Invasive breast cancer and breast cancer death after non-screen detected ductal carcinoma in situ from 1990 to 2018 in England: population based cohort study.
    BMJ. 2024;384:e075498.
    >> Share

  11. SCHMIDT MK, Lips EH, Schmitz RS, Verschuur E, et al
    Invasive breast cancer and breast cancer death after non-screen detected ductal carcinoma in situ.
    BMJ. 2024;384:q22.
    >> Share


    Br J Cancer

  12. MATHIEU E, Noguchi N, Li T, Barratt AL, et al
    Health benefits and harms of mammography screening in older women (75+ years)-a systematic review.
    Br J Cancer. 2024;130:275-296.
    >> Share


    Breast Cancer

  13. HOSHI N, Uemura T, Tachibana K, Abe S, et al
    Endosomal protein expression of gamma1-adaptin is associated with tumor growth activity and relapse-free survival in breast cancer.
    Breast Cancer. 2024 Jan 24. doi: 10.1007/s12282-023-01539.
    >> Share


    Breast Cancer (Dove Med Press)

  14. CHEN CC, Tang WH, Wu CC, Lee TL, et al
    Pretreatment Circulating Albumin, Platelet, and RDW-SD Associated with Worse Disease-Free Survival in Patients with Breast Cancer.
    Breast Cancer (Dove Med Press). 2024;16:23-39.
    >> Share


    Breast Cancer Res

  15. NABILA S, Choi JY, Abe SK, Islam MR, et al
    Differential patterns of reproductive and lifestyle risk factors for breast cancer according to birth cohorts among women in China, Japan and Korea.
    Breast Cancer Res. 2024;26:15.
    >> Share

  16. KANG E, Jung JJ, Lim C, Kim HK, et al
    Increased risk of contralateral breast cancer for BRCA1/2 wild-type, high-risk Korean breast cancer patients: a retrospective cohort study.
    Breast Cancer Res. 2024;26:14.
    >> Share

  17. SUN X, Reiner AS, Tran AP, Watt GP, et al
    A genome-wide association study of contralateral breast cancer in the Women's Environmental Cancer and Radiation Epidemiology Study.
    Breast Cancer Res. 2024;26:16.
    >> Share


    Breast Cancer Res Treat

  18. COOMBES C, Angelou C, Al-Khalili Z, Hart W, et al
    Performance of a novel spectroscopy-based tool for adjuvant therapy decision-making in hormone receptor-positive breast cancer: a validation study.
    Breast Cancer Res Treat. 2024 Jan 20. doi: 10.1007/s10549-023-07229.
    >> Share

  19. SCHWARTZ CJ, Khorsandi N, Blanco A, Mukhtar RA, et al
    Clinicopathologic and genetic analysis of invasive breast carcinomas in women with germline CHEK2 variants.
    Breast Cancer Res Treat. 2024;204:171-179.
    >> Share

  20. ADDAE JK, Sweeting RS, Meszoely IM, McCaffrey RL, et al
    Superparamagnetic iron oxide (SPIO) for axillary mapping in patients with ductal carcinoma in situ undergoing mastectomy: single-institution experience.
    Breast Cancer Res Treat. 2024;204:117-121.
    >> Share

  21. YANUS GA, Sokolenko AP, Imyanitov EN
    Northern origin of the BRCA2 c.5286 T > G founder allele.
    Breast Cancer Res Treat. 2024;204:191.
    >> Share

  22. KESKE A, Weisman P, Ospina-Romero M, Raut P, et al
    Breast cancers in monoallelic MUTYH germline mutation carriers have clinicopathological features overlapping with those in BRCA1 germline mutation carriers.
    Breast Cancer Res Treat. 2024;204:151-158.
    >> Share

  23. MOKBEL K, Alamoodi M
    "Enhancing survival outcomes through breast-conserving therapy in ipsilateral breast tumor recurrence: insights into metastasis and treatment strategies".
    Breast Cancer Res Treat. 2024;204:187.
    >> Share

  24. KARAKAWA R, Konishi T, Yoshimatsu H, Hashimoto Y, et al
    Association between body mass index and outcomes after autologous breast reconstruction: a nationwide inpatient database study in Japan.
    Breast Cancer Res Treat. 2024;204:69-78.
    >> Share

  25. YEH C, Zhou M, Bapodra N, Hershman D, et al
    Analysis of data from the PALOMA-3 trial confirms the efficacy of palbociclib and offers alternatives for novel assessment of clinical trials.
    Breast Cancer Res Treat. 2024;204:39-47.
    >> Share

  26. AL MASRY Z, Pic R, Dombry C, Devalland C, et al
    A new methodology to predict the oncotype scores based on clinico-pathological data with similar tumor profiles.
    Breast Cancer Res Treat. 2024;203:587-598.
    >> Share

  27. ZHAO YY, Ge HJ, Yang WT, Shao ZM, et al
    Secretory breast carcinoma: clinicopathological features and prognosis of 52 patients.
    Breast Cancer Res Treat. 2024;203:543-551.
    >> Share

  28. LEE CS, Goldman L, Grimm LJ, Liu IX, et al
    Screening mammographic performance by race and age in the National Mammography Database: 29,479,665 screening mammograms from 13,181,241 women.
    Breast Cancer Res Treat. 2024;203:599-612.
    >> Share

  29. OPPONG BA, Rumano RP, Paskett ED
    Expanding the use of patient navigation: health coaching-based navigation as a novel approach to addressing deficits in breast cancer survivorship support.
    Breast Cancer Res Treat. 2024 Jan 25. doi: 10.1007/s10549-023-07213.
    >> Share

  30. CETIN K, Kokten S, Sarikamis B, Yildirim S, et al
    The association of PD-L1 expression and CD8-positive T cell infiltration rate with the pathological complete response after neoadjuvant treatment in HER2-positive breast cancer.
    Breast Cancer Res Treat. 2024 Jan 25. doi: 10.1007/s10549-023-07242.
    >> Share

  31. LICATA L, De Sanctis R, Vingiani A, Cosentini D, et al
    Real-world use of multigene signatures in early breast cancer: differences to clinical trials.
    Breast Cancer Res Treat. 2024 Jan 24. doi: 10.1007/s10549-023-07227.
    >> Share

  32. VAN DE LOO ME, Andour L, van Heesewijk AE, Oosterkamp HM, et al
    Neoadjuvant endocrine treatment in hormone receptor-positive breast cancer: Does it result in more breast-conserving surgery?
    Breast Cancer Res Treat. 2024 Jan 24. doi: 10.1007/s10549-023-07222.
    >> Share

  33. NASRAZADANI A, Marti JLG, Lathrop K, Restrepo A, et al
    Poziotinib treatment in patients with HER2-positive advanced breast cancer who have received prior anti-HER2 regimens.
    Breast Cancer Res Treat. 2024 Jan 23. doi: 10.1007/s10549-023-07236.
    >> Share


    Cancer

  34. PRINSLOO S, Kaptchuk TJ, De Ridder D, Lyle R, et al
    Brain-computer interface relieves chronic chemotherapy-induced peripheral neuropathy: A randomized, double-blind, placebo-controlled trial.
    Cancer. 2024;130:300-311.
    >> Share

  35. QU F, Lu R, Liu Q, Wu X, et al
    Antibody-drug conjugates transform the outcome of individuals with low-HER2-expression advanced breast cancer.
    Cancer. 2024 Jan 25. doi: 10.1002/cncr.35205.
    >> Share

  36. XIONG W, Xu T, Liu X, Zhang L, et al
    Efficacy and safety of nanoparticle albumin-bound paclitaxel in taxane-pretreated metastatic breast cancer patients.
    Cancer. 2024 Jan 25. doi: 10.1002/cncr.35206.
    >> Share


    Cancer Epidemiol Biomarkers Prev

  37. ZELDIN J, Sandler DP, Ogunsina K, O'Brien KM, et al
    Association of fibroids, endometriosis, and gynecologic surgeries with breast cancer incidence and hormone receptor subtypes.
    Cancer Epidemiol Biomarkers Prev. 2024.
    >> Share


    Cancer Lett

  38. JIA F, Sun S, Li J, Wang W, et al
    Neoadjuvant chemotherapy-induced remodeling of human hormonal receptor-positive breast cancer revealed by single-cell RNA sequencing.
    Cancer Lett. 2024 Jan 22:216656. doi: 10.1016/j.canlet.2024.216656.
    >> Share


    Clin Breast Cancer

  39. ROLLIN FG, Lee-Rey S, Wong-Serrano E, Habert S, et al
    The Importance of Naming Structural Racism as a Root Cause of Racial Inequities in Breast Cancer Outcomes.
    Clin Breast Cancer. 2024 Jan 14:S1526-8209(24)00007.
    >> Share


    Eur J Cancer

  40. GIORGI ROSSI P, Mancuso P, Pattacini P, Campari C, et al
    Comparing accuracy of tomosynthesis plus digital mammography or synthetic 2D mammography in breast cancer screening: baseline results of the MAITA RCT consortium.
    Eur J Cancer. 2024;199:113553.
    >> Share

  41. TOLANEY SM, Guarneri V, Seo JH, Cruz J, et al
    Long-term patient-reported outcomes from monarchE: Abemaciclib plus endocrine therapy as adjuvant therapy for HR+, HER2-, node-positive, high-risk, early breast cancer.
    Eur J Cancer. 2024;199:113555.
    >> Share


    Eur J Surg Oncol

  42. CAVALCANTE FP, Zerwes FP, Souza ABA, Ziegelmann PK, et al
    The use of blue dye alone for sentinel lymph node biopsy after neoadjuvant chemotherapy in patients with initially node-positive breast cancer.
    Eur J Surg Oncol. 2024;50:107967.
    >> Share


    Eur Radiol

  43. DENG Y, Lu Y, Li X, Zhu Y, et al
    Prediction of human epidermal growth factor receptor 2 (HER2) status in breast cancer by mammographic radiomics features and clinical characteristics: a multicenter study.
    Eur Radiol. 2024 Jan 26. doi: 10.1007/s00330-024-10607.
    >> Share

  44. STEYEROVA P, Kaidar-Person O, Pinker K, Dubsky P, et al
    Breast cancer: evaluating the axilla before, during, and after therapy-new challenges.
    Eur Radiol. 2024 Jan 26. doi: 10.1007/s00330-024-10621.
    >> Share


    Gene

  45. KONG L, Jin X
    Dysregulation of deubiquitination in breast cancer.
    Gene. 2024 Jan 17:148175. doi: 10.1016/j.gene.2024.148175.
    >> Share


    Int J Cancer

  46. SCHMIDT ME, Maurer T, Behrens S, Seibold P, et al
    Cancer-related fatigue: Towards a more targeted approach based on classification by biomarkers and psychological factors.
    Int J Cancer. 2024;154:1011-1018.
    >> Share


    J Clin Oncol


  47. Erratum: Development and Validation of a Genomic Profile for the Omission of Local Adjuvant Radiation in Breast Cancer.
    J Clin Oncol. 2024 Jan 22:JCO2400028. doi: 10.1200/JCO.24.00028.
    >> Share

  48. SLAMON DJ, Dieras V, Rugo HS, Harbeck N, et al
    Overall Survival With Palbociclib Plus Letrozole in Advanced Breast Cancer.
    J Clin Oncol. 2024 Jan 22:JCO2300137. doi: 10.1200/JCO.23.00137.
    >> Share


    J Nucl Med

  49. YEH R, O'Donoghue JA, Jayaprakasam VS, Mauguen A, et al
    First-in-Human Evaluation of Site-Specifically Labeled (89)Zr-Pertuzumab in Patients with HER2-Positive Breast Cancer.
    J Nucl Med. 2024 Jan 25:jnumed.123.266392. doi: 10.2967/jnumed.123.266392.
    >> Share


    J Surg Oncol

  50. SARKAR P, Huffman KN, Williams T, Deol A, et al
    Rates of breast reconstruction uptake and attitudes toward breast cancer and survivorship among south asians: A literature review.
    J Surg Oncol. 2024 Jan 21. doi: 10.1002/jso.27584.
    >> Share


    Lancet

  51. BRAUNSTEIN LZ
    Optimising adjuvant breast radiotherapy via preoperative imaging.
    Lancet. 2023 Dec 5:S0140-6736(23)02698-3. doi: 10.1016/S0140-6736(23)02698.
    >> Share


    Mod Pathol

  52. SIQUEIRA JM, Mitani Y, Hoff CO, Bonini F, et al
    Analysis of B7-H4 Expression Across Salivary Gland Carcinomas Reveals Adenoid Cystic Carcinoma-Specific Prognostic Relevance.
    Mod Pathol. 2024;37:100371.
    >> Share


    Nature

  53. CHO MG, Kumar RJ, Lin CC, Boyer JA, et al
    MRE11 liberates cGAS from nucleosome sequestration during tumorigenesis.
    Nature. 2024;625:585-592.
    >> Share


    NPJ Breast Cancer

  54. JANSSEN LM, Janse MHA, Penning de Vries BBL, van der Velden BHM, et al
    Predicting response to neoadjuvant chemotherapy with liquid biopsies and multiparametric MRI in patients with breast cancer.
    NPJ Breast Cancer. 2024;10:10.
    >> Share

  55. HOOK C, Chatterjee U, Sheng H, Zhu Q, et al
    A polygenic score associated with fracture risk in breast cancer patients treated with aromatase inhibitors.
    NPJ Breast Cancer. 2024;10:9.
    >> Share

  56. MCCANN KE, Goldfarb SB, Traina TA, Regan MM, et al
    Selection of appropriate biomarkers to monitor effectiveness of ovarian function suppression in pre-menopausal patients with ER+ breast cancer.
    NPJ Breast Cancer. 2024;10:8.
    >> Share


    Oncol Rep

  57. YU H, Bian Q, Wang X, Wang X, et al
    Bone marrow stromal cell antigen 2: Tumor biology, signaling pathway and therapeutic targeting (Review).
    Oncol Rep. 2024;51:45.
    >> Share

  58. LEI S, Li S, Xiao W, Jiang Q, et al
    [Corrigendum] Azurocidin 1 inhibits the aberrant proliferation of triple?negative breast cancer through the regulation of pyroptosis.
    Oncol Rep. 2024;51:49.
    >> Share


    PLoS Comput Biol

  59. ZOU J, Shah O, Chiu YC, Ma T, et al
    Systems approach for congruence and selection of cancer models towards precision medicine.
    PLoS Comput Biol. 2024;20:e1011754.
    >> Share


    PLoS One

  60. MIGOWSKI A, Nadanovsky P, Manso de Mello Vianna C
    Harms and benefits of mammographic screening for breast cancer in Brazil.
    PLoS One. 2024;19:e0297048.
    >> Share

  61. SHAHMIRZALOU P, Rasekhi A, Jafari Khaledi M, Khayamzadeh M, et al
    Comparison performance of the Bayesian Approach with the Weibull and Birnbaum-Saunders distributions in imputation of time-to-event censors.
    PLoS One. 2024;19:e0295977.
    >> Share

  62. ZARIF S, Abdulkader H, Elaraby I, Alharbi A, et al
    Using hybrid pre-trained models for breast cancer detection.
    PLoS One. 2024;19:e0296912.
    >> Share


    Proc Natl Acad Sci U S A

  63. BAGHDASARYAN A, Liu H, Ren F, Hsu R, et al
    Intratumor injected gold molecular clusters for NIR-II imaging and cancer therapy.
    Proc Natl Acad Sci U S A. 2024;121:e2318265121.
    >> Share

  64. WANG Y, Xu Z, Wu KL, Yu L, et al
    Siglec-15/sialic acid axis as a central glyco-immune checkpoint in breast cancer bone metastasis.
    Proc Natl Acad Sci U S A. 2024;121:e2312929121.
    >> Share


    Radiology

  65. ZHOU W, Rahbar H
    Quantitative Breast Parenchymal Enhancement to Predict Breast Cancer Recurrence.
    Radiology. 2024;310:e240021.
    >> Share

  66. AREFAN D, Zuley ML, Berg WA, Yang L, et al
    Assessment of Background Parenchymal Enhancement at Dynamic Contrast-enhanced MRI in Predicting Breast Cancer Recurrence Risk.
    Radiology. 2024;310:e230269.
    >> Share


    Semin Oncol

  67. WEKKING D, Lambertini M, Dessi M, Denaro N, et al
    CDK4/6 inhibitors in the treatment of metastatic breast cancer: Focus on toxicity and safety.
    Semin Oncol. 2024 Jan 13:S0093-7754(24)00002.
    >> Share


Free Medical Abstracts
Privacy Policy
Sponsors
Share

© Amedeo 1997-2016